Regen BioPharma Scheduled to Make Presentation at American Society for Hematology's 56th Annual Meeting in San Francisco December 6th - 9th

SAN DIEGO, CA--(Marketwired - Dec 1, 2014) - Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage." The work will be presented on Saturday December 6, 2014 at the West Building, Level 1 in the Moscone Center, San Francisco at 5:30 PM.

Results presented will include demonstration that bone marrow cells genetically engineered to express the NR2F6 gene cause healthy cells to turn leukemic when implanted into mice. The process by which the NR2F6 gene causes healthy cells to become leukemic is associated with blocking the ability of the bone marrow cells to make red blood cells. This instead causes production of immature cells termed "proerythroblasts." Furthermore, the study demonstrates that, at a molecular level, the protein made by the NR2F6 gene needs to bind DNA in order for healthy cells to turn leukemic.

"While chemotherapy and radiation therapy non-selectively kill all replicating cells, both cancer and healthy cells, thus causing severe toxicity, targeted therapies such as kinase inhibitors (e.g.: Gleevec by Novartis $4.7 billion in 2012)¹ and proteasome inhibitors (e.g.: Velcade by J&J and Takeda $2.3 billion in sales in 2012)² specifically inhibit molecular processes of cancer cells but not other multiplying cells in the body. Dr. Christine Ichim found that the NR2F6 gene is essential for the process of cancer formation, thus potentially offering a new target for development of targeted therapies," said Dr. Thomas Ichim, Regen BioPharma's Chief Scientific Officer.

"It is important to note that when inhibition of this gene with gene silencing was performed, the leukemic cells reverted back to a state resembling non-malignant cells. Thus we believe that developing therapies that block NR2F6 could lead to a whole new class of targeted therapeutics," according to Christine Ichim, PhD.

Currently Regen BioPharma is developing small molecule inhibitors of NR2F6, as well as shRNA gene-silencing of this gene. Gene-silencing has previously been utilized by Regen BioPharma in development of its dCellVax breast cancer vaccine IND application, as well as in peer-reviewed publications that Regen has co-authored^{3, 4}.